Villarroel-Espindola, F. (Franz)

Filtering

2019 - 201912020 - 20221

Settings

Author search.filters.isAuthorOfPublication.a203ae5b-af02-496b-8281-3f88dbb76319

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma
    (Nature Publishing Group, 2019) Berraondo, P. (Pedro); Perez-Gracia, J.L. (Jose Luis); Rodriguez-Ruiz, M.E. (María Esperanza); Lopez-Diaz-de-Cerio, A. (Ascensión); Tejada-Solis, S. (Sonia); Diez-Valle, R. (Ricardo); Goicoechea, I. (Iosune); Inoges, S. (Susana); Gurpide, A. (Alfonso); Melero, I. (Ignacio); Choi, J. (Jungmin); Porciuncula, A. (Angelo); Idoate, M.A. (Miguel Ángel); Andrea, C.E. (Carlos Eduardo) de; López-Janeiro, Á. (Álvaro); Gallego-Perez-Larraya, J. (Jaime); Villarroel-Espindola, F. (Franz); Schalper, K.A. (Kurt A.); Giraldez, M. (Miriam); Fernandez-Sanmamed, M. (Miguel)
    Glioblastoma is the most common primary central nervous system malignancy and has a poor prognosis. Standard first-line treatment, which includes surgery followed by adjuvant radio-chemotherapy, produces only modest benefits to survival1,2. Here, to explore the feasibility, safety and immunobiological effects of PD-1 blockade in patients undergoing surgery for glioblastoma, we conducted a single-arm phase II clinical trial (NCT02550249) in which we tested a presurgical dose of nivolumab followed by postsurgical nivolumab until disease progression or unacceptable toxicity in 30 patients (27 salvage surgeries for recurrent cases and 3 cases of primary surgery for newly diagnosed patients). Availability of tumor tissue pre- and post-nivolumab dosing and from additional patients who did not receive nivolumab allowed the evaluation of changes in the tumor immune microenvironment using multiple molecular and cellular analyses. Neoadjuvant nivolumab resulted in enhanced expression of chemokine transcripts, higher immune cell infiltration and augmented TCR clonal diversity among tumor-infiltrating T lymphocytes, supporting a local immunomodulatory effect of treatment. Although no obvious clinical benefit was substantiated following salvage surgery, two of the three patients treated with nivolumab before and after primary surgery remain alive 33 and 28 months later.
  • Thumbnail Image
    The armed conflict and the impact on patients with cancer in Ukraine: urgent considerations
    (2022) Gandara, D.R. (David R.); Gil-Bazo, I. (Ignacio); Ubillos, L. (Luis); Santos, E. (Edgardo); Reyes-Cosmelli, F. (Felipe); Aboitiz, F. (Francisco); Mountzios, G. (Giannis); Morgan, G. (Gilberto); Arrieta, Ó. (Óscar); Subbiah, V. (Vivek); Mahave, M. (Mauricio); Caglevic, C. (Christian); Rolfo, C. (Christian); Sapunar, J. (Jorge); Alatorre, J. (Jorge); Addeo, A. (Alfredo); Bretel, D. (Denisse); Tan, D.S.W. (Daniel S. W.); Novello, S. (Silvia); Corrales, L. (Luis); Morales, R. (Ricardo); Garassino, M. C. (Mariana-Chiara); Hirsch, F. R. (Fred R.); Zielinski, C. (Christoph); Villarroel-Espindola, F. (Franz); Cardona, A. (Andrés); Leighl, N.B. (Natasha B.); Raez, L. (Luis); Liu, S.V. (Stephen V.)
    On February 24, 2022, a war began within the Ukrainian borders. At least 3.0 million Ukrainian inhabitants have already fled the country. Critical infrastructure, including hospitals, has been damaged. Children with cancer were urgently transported to foreign countries, in an effort to minimize interruption of their life-saving treatments. Most adults did not have that option. War breeds cancer-delaying diagnosis, preventing treatment, and increasing risk. We project that a modest delay in care of only 4 months for five prevalent types of cancer will lead to an excess of over 3,600 cancer deaths in the subsequent years. It is critical that we establish plans to mitigate that risk as soon as possible.